Last Updated: November 9, 2026

AMICAR Drug Patent Profile

« Back to Dashboard


Which patents cover Amicar, and when can generic versions of Amicar launch?

Amicar is a drug marketed by Epic Pharma Llc and Hikma and is included in three NDAs.

The generic ingredient in AMICAR is aminocaproic acid. There is one drug master file entry for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the aminocaproic acid profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Amicar

A generic version of AMICAR was approved as aminocaproic acid by LUITPOLD on December 1st, 1987.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for AMICAR?
  • What are the global sales for AMICAR?
  • What is Average Wholesale Price for AMICAR?
Summary for AMICAR
Recent Clinical Trials for AMICAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universidad Autonoma de Nuevo LeonPhase 2
The University of Texas Health Science Center at San AntonioPhase 1
Duke UniversityPhase 4

See all AMICAR clinical trials

US Patents and Regulatory Information for AMICAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epic Pharma Llc AMICAR aminocaproic acid INJECTABLE;INJECTION 015229-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma AMICAR aminocaproic acid TABLET;ORAL 015197-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma AMICAR aminocaproic acid SOLUTION;ORAL 015230-002 Approved Prior to Jan 1, 1982 AA RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma AMICAR aminocaproic acid TABLET;ORAL 015197-002 Jun 24, 2004 AB RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.